KZIA beat EPS expectations by 29.48%
Jul 10, 2025, 10:34 AM
0.00%
What does KZIA do
Kazia Therapeutics, based in Sydney, Australia, focuses on oncology drug development, with lead programs including Paxalisib for brain cancer and EVT801 for inhibiting tumor blood vessel growth. The company targets diseases like brain, renal, and liver cancers.
Kazia Therapeutics (KZIA) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Kazia Therapeutics's actual EPS was -$12.30, beating the estimate of -$17.44 per share, resulting in a 29.48% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.